[How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
Domènech
Eugeni
E
López San Román
Antonio
A
Garcia-Planella
Esther
E
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy / Q000628:therapy; D004334:Drug Administration Schedule; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000628:therapy*; D000069285:Infliximab; D017410:Practice Guidelines as Topic
D000911:Antibodies, Monoclonal; D001688:Biological Products; D007155:Immunologic Factors; D000069285:Infliximab; D001379:Azathioprine